Leerink Partners analyst Mike Kratky has reiterated their bullish stance on NPCE stock, giving a Buy rating yesterday.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Mike Kratky has given his Buy rating due to a combination of factors including NeuroPace’s impressive financial performance and strategic initiatives. The company reported first-quarter 2025 sales that exceeded consensus expectations, driven by robust growth in its RNS business. Additionally, NeuroPace’s gross margin for the quarter was notably higher than anticipated, which reflects improved manufacturing efficiencies and effective cost management.
Furthermore, the management’s decision to raise the full-year 2025 sales guidance signals confidence in continued business momentum. The potential for gross margin expansion in the following year, particularly as the company phases out its lower-margin DIXI partnership, adds to the positive outlook. The anticipated expansion into generalized epilepsy, supported by the upcoming NAUTILUS submission to the FDA, further strengthens the growth prospects for NeuroPace.
In another report released yesterday, Wells Fargo also maintained a Buy rating on the stock with a $17.00 price target.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NPCE in relation to earlier this year.